CCL22 and melanoma: This discrepancy might be caused by the different sources of CXCL10 and CCL22, such as dendritic cells and endothelial cells that express lower levels of PD1 (29), leading to no effect of anti-PD1 antibody on the production of these chemokines in melanoma patients.